OBJECTIVE: To compare the efficacy of @entity14319 plus orchidectomy with orchidectomy alone in the management of advanced @entity263 . @entity1 AND METHODS: Fifty-four @entity1 with histologically confirmed metastatic @entity263 ( @entity70402 ) and a performance status of 0-2 (World Health Organization) were entered into the trial between March 2000 and June 2002. The trial comprised two treatment arms, i.e. @entity1 were randomized to orchidectomy alone or orchidectomy plus @entity14319 (OL), each of 27 @entity1 . @entity14319 was started on the day of orchidectomy at 2 mg twice daily. @entity1 were evaluated clinically before and every 3 months after the intervention, with measurements of @entity1486 , a bone scan and uroflowmetry, with the clinical response assessed as the change in these variables. RESULTS: At 6 months there was a significant reduction in @entity1486 level in both treatments, but more marked in the OL group (mean 9.1 and 26.4 ng/mL, P = 0.9). After 2 years these changes were more consistent in the OL group (mean 3.01 and 9.02 ng/mL; P < 0.001). Eleven (40%) @entity1 in orchidectomy and 21 (78%) in the OL group had a complete @entity1486 response (P < 0.05), with a partial response in nine (33%) and four (15%), and progression in seven (25%) and two (7%), respectively (P < 0.05). Bone scans showed that in the orchidectomy arm only four (15%) @entity1 had a complete response, vs eight (30%) in the OL group (P < 0.02), with a partial response in 19 (70%) and 17 (63%), and progression in four (15%) and two (7%), respectively (P < 0.02). There was a significant improvement in peak flow rate in the OL group, with a mean difference of +1.17 mL/s (P < 0.04). Of the 54 @entity1 who entered the trial, 19 (35%) died, 12 (22%) in orchidectomy and seven (13%) in OL group (P < 0.001). CONCLUSION: Adding @entity14319 to orchidectomy produced a more reliable and consistent decrease in serum @entity1486 level; it not only shrinks the primary @entity5 but also diminishes the secondary @entity5 , providing better relief from @entity158 and lower urinary tract symptoms, and improving survival compared with orchidectomy alone.

A comparison of XXXX and orchidectomy vs orchidectomy alone in the management of advanced @entity263 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity70402 :: ('OMIM:227646', 'Disease') :: ['M1b or D2'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostatic cancer', 'prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour'] @entity158 :: ('MESH:D010146', 'Disease') :: ['bone pain'] @entity14319 :: ('MESH:C015329', 'Chemical') :: ['lycopene', 'Lycopene'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen (PSA)', 'PSA']
@entity14319 :: (MESH:C015329,Chemical) :: ['lycopene']
